SAB Biotherapeutics (SABSW) Stock Analysis

What SAB Biotherapeutics does

SAB Biotherapeutics, Inc. is a biopharmaceutical firm specializing in the development of immunotherapies. Their efforts are directed towards combating various health challenges, such as infectious and autoimmune diseases, as well as oncology. Among their notable therapeutic candidates are SAB-142, an anti-thymocyte globulin intended for Type 1 diabetes; SAB-176, which targets seasonal influenza; and SAB-301, developed to counter Middle East Respiratory Syndrome Coronavirus (MERS-COV). Founded in 2014, the company's headquarters are located in Sioux Falls, South Dakota, with a secondary office situated in Cambridge, Massachusetts.

Key metrics

ETFs linked to SABSW

Broad-market and Healthcare sector ETFs an investor holding SAB Biotherapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SABSW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for SAB Biotherapeutics?

SAB Biotherapeutics trades under the ticker SABSW on NASDAQ.

Which exchange is SABSW listed on?

SABSW is listed on NASDAQ.

What sector does SAB Biotherapeutics operate in?

SAB Biotherapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SABSW in a portfolio?

PortView shows SABSW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.